Relative risk of new-onset diabetes during the first year after renal transplantation in patients receiving tacrolimus or cyclosporine immunosuppression

Clinical Transplantation

Volumn 20, Issue 5, 2006, Pages 659-664

  Hoitsma, Andries J ^a   Hilbrands, Luuk B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cyclosporine; Diabetes; Diabetes mellitus; Kidney transplantation; New onset diabetes; Renal transplantation; Tacrolimus

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; GLUCOSE; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORAL ANTIDIABETIC AGENT; STEROID; TACROLIMUS;

ADULT; AGE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; CYCLOSPORINE; DIABETES MELLITUS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TACROLIMUS; TIME FACTORS;

EID: 33748665445     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00535.x     Document Type: Article

References (30)

1. Meier -K riesche H-U, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004: 4: 1289.
2. Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
3. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease -major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995: 60: 451.
4. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998: 9 (Suppl. 12): S16.
5. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000: 11: 1735.
6. Ducloux D, Kazory A, Chalopin J-M. Predicting coronary heart disease in renal transplant recipients: A prospective study. Kidney Int 2004: 66: 441.
7. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003: 3: 1178.
8. Miles AM, Sumrani N, Horowitz R et al. Diabetes mellitus after renal transplantation: As deleterious as non-transplant associated diabetes? Transplantation 1998: 65: 380.
9. Davidson J, Wilkinson A, Dantal J et al. New-onset diabetes after transplantation: 2003 international consensus guidelines. Transplantation 2003: 75 (Suppl.): SS3.
10. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post-transplant diabetes: A systematic review of the literature. Diabetes Care 2002: 25: 583.
11. Heisel O, Heisel R, Balshaw R, Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: A systematic review and meta-analysis. Am J Transplant 2004: 4: 583.
12. ter Meulen CG, van Riemsdijk I, Hene RJ et al. Steroid-withdrawal at 3d after renal transplantation with anti-IL-2 receptor alpha therapy: A prospective, randomized, multicenter study. Am J Transplant 2005: 5: 639.
13. De Sévaux R, Smak Gregoor PJH, H enéRJ et al. A controlled trial comparing two doses of cyclosporine in conjunction with Mycophenolate Mofetil and corticosteroids. J Am Soc Nephrol 2001: 12: 1750.
14. Gregoor PJ, de Sevaux RG, Hene RJ et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999: 68: 1603.
15. Woodward RS, Schnitzler MA, Baty J et al. Incidence and cost of new onset diabetes mellitus. Am J Transplant 2003: 3: 590.
16. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997: 16: 242.
17. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996: 15: 135.
18. Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997: 64: 979.
19. Vesco L, Busson M, Bedrossian J, Bitker MO, Hiesse C, Lang P. Diabetes mellitus after renal transplantation: Characteristics, outcome and risk factors. Transplantation 1996: 61: 1475.
20. Sumrani NB, Delaney V, Ding ZK et al. Diabetes mellitus after renal transplantation in the cyclosporine era - an analysis of risk factors. Transplantation 1991: 51: 343.
21. Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992: 53: 889.
22. Ricordi C, Zeng Y, Alejandro R et al. In vivo effect of F506 on human pancreatic islets. Transplantation 1991: 52: 519.
23. Laskow DA, Vincenti F, Neylan JF, Mendez R, Matas AJ. An open-label concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation 1996: 62: 900.
24. Paolillo JA, Boyle GJ, Law YM et al. Posttransplant diabetes in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. Transplantation 2001: 71: 252.
25. Baid-Agrawal S, Delmonico FL, Tolkoff-Rubin NE et al. Cardiovascular risk profile after conversion from cyclosporine A to tacrolimus in stable renal transplant recipients. Transplantation 2004: 27: 1199.
26. Artz MA, Boots JM, Ligtenberg G et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004: 4: 937.
27. White M, Haddad H, Leblanc MH et al. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: The Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion. J Heart Lung Transplant 2005: 24: 798.
28. Hathaway DK, Tolley EA, Blakely ML, Winsett RP, Gaber AO. Development of an index to predict posttransplant diabetes mellitus. Clin Transplant 1993: 7: 330.
29. Paty BW, Harmon JS, Marsh CL, Robertson RP. Inhibitory effects of immunosuppressive drugs on insulin secretion from HIT-T15 cells and Wistar rat islets. Transplantation 2002: 73: 353.
30. Wilkinson A, Davidson J, Dotta F et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005: 19: 291.